Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Next Previous
X
Search
Trial Profile

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Tisotumab-vedotin (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Pancreatic cancer; Pharyngeal neoplasms; Solid tumours; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms innovaTV 207
  • Sponsors Seagen

    • Most Recent Events

    • 04 Jun 2024 Updated results from the full cohort, Part C, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2024 According to a Genmab media release, the results from this trial presented in a rapid oral session at 2024 ASCO Annual Meeting.
    • 03 Jun 2024 Results of Part C(n=40) from this trial presented in the Genmab Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top